Effects of perzinfotel, butorphanol tartrate, and a butorphanol-perzinfotel combination on the minimum alveolar concentration of isoflurane in cats.
Zwijnenberg
Raphael J
RJ
Pfizer Animal Health Australia, West Ryde, NSW, Australia. raphael.j.zwijnenberg@pfizer.com
L del Rio
Carlos
C
Pollet
Robert A
RA
Muir
William W
WW
D000818:Animals; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002077:Butorphanol / Q000494:pharmacology*; D002415:Cats; D003243:Consciousness / Q000187:drug effects* / Q000502:physiology; D018592:Cross-Over Studies; D004338:Drug Combinations; D004558:Electric Stimulation; D005260:Female; D007530:Isoflurane / Q000378:metabolism*; D008297:Male; D009061:Mouth Mucosa / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects; D063065:Organophosphonates / Q000494:pharmacology*; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects; D013686:Telemetry
D053961:Azabicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004338:Drug Combinations; D063065:Organophosphonates; D007530:Isoflurane; C110623:EAA-090; D002077:Butorphanol